TY - JOUR
T1 - Molecular pathways of pancreatic carcinogenesis
AU - Fernandez-Zapico, Martin E.
AU - Urrutia, Raul
N1 - Funding Information:
This work was supported by the Mayo Foundation, Lustgarten Foundation for Pancreatic Cancer Research and by grants, DK52913 and DK56620, from the National Institutes of Health to R.U.
PY - 2004/11
Y1 - 2004/11
N2 - Pancreatic cancer has one of the poorest prognoses among human neoplasms, with an overall five-year survival rate of 3%. Thus, there are significant efforts to understand the molecular mechanisms underlying the development pancreatic cancer that might lead to effective diagnostic and treatment strategies that improve the prognosis of the disease. In this review, we discuss signaling pathways that control cell growth, differentiation and migration that are dysregulated in this cancer. Particular emphasis is given to the potential there is to manipulate these pathways for therapeutic purposes.
AB - Pancreatic cancer has one of the poorest prognoses among human neoplasms, with an overall five-year survival rate of 3%. Thus, there are significant efforts to understand the molecular mechanisms underlying the development pancreatic cancer that might lead to effective diagnostic and treatment strategies that improve the prognosis of the disease. In this review, we discuss signaling pathways that control cell growth, differentiation and migration that are dysregulated in this cancer. Particular emphasis is given to the potential there is to manipulate these pathways for therapeutic purposes.
UR - http://www.scopus.com/inward/record.url?scp=23744433866&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23744433866&partnerID=8YFLogxK
U2 - 10.1016/j.ddmec.2004.09.003
DO - 10.1016/j.ddmec.2004.09.003
M3 - Review article
AN - SCOPUS:23744433866
SN - 1740-6765
VL - 1
SP - 247
EP - 252
JO - Drug Discovery Today: Disease Mechanisms
JF - Drug Discovery Today: Disease Mechanisms
IS - 2
ER -